Tag: neuroscience

May 9, 2018

Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update

Prothena (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan...
April 30, 2018

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...
April 23, 2018

Big Pharma M&A: Shire Reviews Fourth Acquisition Proposal from Takeda

Takeda Pharmaceuticals may become a top global drugmaker with positions in treatments for cancers, gastrointestinal diseases and nervous-system disorders.
April 17, 2018

Shire Receives FDA Approval for Rare Disease Drug, Share Price Rises

Shire has received another FDA approval with the second approval for Vonvendi, a treatment for perioperative bleeding management in adults...
April 9, 2018

AveXis’ Share Price Soars with Acquisition Announcement

Global big pharma company Novartis started the week off on the right foot by announcing plans to acquire gene therapy...
March 21, 2018

Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene

Prothena Corporation (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the...
March 14, 2018

Biogen Announces Voluntary Drug Withdrawal and Pfizer Drug Acquisition Weeks Apart, Share Price Remains Steady

March has been a busy month for Biogen with its voluntary withdrawal of Zinbryta and its acquisition of Pfizer's PF-04958242.